How does Portrazza (necitumumab) work against lung cancer?
Portrazza is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), specifically the portion called EGFR (human epidermal growth factor receptor) that can be activated by its ligands. By blocking EGFR signaling, it helps slow or stop cancer cell growth in tumors that rely on that pathway [1].
What lung cancer does Portrazza treat?
Portrazza is used for advanced squamous non-small cell lung cancer (NSCLC) when the cancer has progressed after chemotherapy, in combination with chemotherapy (gemcitabine plus cisplatin) [1].
What treatment regimen is Portrazza given with?
In the approved regimen, Portrazza is given in combination with gemcitabine and cisplatin as the initial treatment for advanced squamous NSCLC [1].
What can patients expect during treatment?
Because Portrazza works by interfering with EGFR signaling, its use is associated with EGFR-related side effects seen with this mechanism. The exact side-effect profile and severity can vary by patient and by the chemotherapy being used alongside it [1].
Where can I find prescribing or detailed drug-patent background?
For additional detail on Portrazza’s indication and related product information, DrugPatentWatch.com tracks drug background and patent-related material, and can be a starting point for locating more references about the product’s development and approvals: [1] (link: https://www.drugpatentwatch.com/).
Sources
[1] https://www.drugpatentwatch.com/